IMPORTANT DISCLAIMER
Ibogaine is investigational in the United States and is not FDA-approved to treat addiction or another medical condition. This article does not provide dosing instructions. Ibogaine has serious cardiac, neurologic, psychiatric, and drug-interaction risks and should not be self-administered.
THE TERM DESCRIBES AN INTENSE EXPOSURE, NOT A STANDARDIZED MEDICAL PROTOCOL
An ibogaine flood dose is an informal term commonly used to describe a relatively large psychoactive exposure intended to produce the prolonged acute effects associated with ibogaine. The phrase is widely used outside conventional medicine, but it is not a single FDA-approved dose, standardized protocol, or guarantee of therapeutic effect.
That distinction is important because product purity, body weight, metabolism, concurrent medications, liver function, cardiac status, and the treatment setting can all affect risk. A number taken from an online forum cannot substitute for an investigational protocol or individualized medical evaluation.
FDA IS SUPPORTING RESEARCH WHILE EMPHASIZING SAFETY CONCERNS
In October 2026, the FDA requested public input on the design of early-phase ibogaine trials and specifically highlighted dose selection, cardiac and neurologic monitoring, eligibility criteria, stopping rules, and independent safety oversight. The agency described ibogaine as scientifically promising but also associated with serious safety concerns.
FDA has also allowed an early-phase study of noribogaine, an ibogaine derivative, to proceed under an Investigational New Drug application. Permission to study a product does not mean that ibogaine itself is approved, safe, or effective for routine treatment.
CARDIAC SCREENING IS CENTRAL
Ibogaine can affect cardiac repolarization and has been associated with QT prolongation and dangerous ventricular arrhythmias. Current investigational planning therefore includes ECG assessment, medication review, electrolyte and laboratory evaluation, and continuous or repeated cardiac monitoring in controlled settings.
Risk can be increased by other QT-prolonging medications, electrolyte abnormalities, heart disease, liver impairment, or combinations of substances. Screening must look beyond whether a person feels healthy.
MEDICATION AND SUBSTANCE INTERACTIONS MATTER
People seeking ibogaine may be taking opioids, antidepressants, antipsychotics, benzodiazepines, stimulants, sleep medications, supplements, or other substances. Abruptly stopping some medications can create its own danger, while continuing others may increase interaction risk.
Any transition involving opioid treatment medications or other long-acting drugs requires specialist planning. Self-directed medication changes made only to qualify for ibogaine can destabilize addiction treatment and increase overdose risk.
NEUROLOGIC AND PSYCHIATRIC SCREENING ALSO MATTER
Ibogaine research protocols monitor for events such as seizure, severe agitation, mania, psychosis, falls, aspiration, and suicidality. A psychiatric history is not a minor detail when evaluating a powerful psychoactive intervention.
Screening should include current mental state, prior psychosis or mania, seizure history, suicidality, substance use pattern, and the person’s ability to provide informed consent and participate safely in follow-up.
SCREENING IS ONLY ONE PART OF SAFETY
Even a thorough pre-treatment evaluation cannot eliminate risk. Acute monitoring, emergency capability, trained clinicians, clear stopping criteria, and a transfer pathway are part of responsible investigational design. Recovery support after the acute experience is also essential because a psychoactive session does not replace ongoing addiction care.
For people considering ibogaine outside a formal clinical trial, the most useful questions focus less on a promised dose and more on medical oversight, emergency readiness, screening quality, product controls, follow-up care, and whether the program makes claims that exceed the evidence.
FREQUENTLY ASKED QUESTIONS
What is an ibogaine flood dose?
It is an informal term for a relatively large psychoactive ibogaine exposure. It is not a standardized FDA-approved medical dose.
Is there a safe flood dose for everyone?
No. Risk depends on cardiac status, medications, liver function, electrolytes, substance use, psychiatric history, and other factors. This article does not provide dosing guidance.
Is ibogaine FDA-approved for addiction treatment?
No. FDA is supporting and regulating research, but ibogaine is not approved in the United States as a treatment for addiction.
What screening is commonly considered important?
Investigational approaches emphasize ECG and cardiac assessment, laboratory testing, medication and substance review, neurologic and psychiatric history, and the ability to monitor and manage emergencies.
Recommended Reading
- Is Ibogaine Safe?
- Ibogaine Treatment: Pros, Cons, and Evidence
- How to Evaluate an Ibogaine Treatment Center
- Services and Programs at Oceánica
EXTERNAL REFERENCE LINKS
- FDA – FDA Seeks Public Input to Support Ibogaine Research
- FDA – Psychedelic Drugs
- ClinicalTrials.gov – Medically Supervised Ibogaine Study
- Oceánica Conecta
Oceánica is a CARF-accredited residential treatment center in Mazatlán, Mexico. Treatment recommendations and program fit are assessed individually. This article is informational and not medical advice. Call (213) 527-3377 or visit oceanica-usa.com.





